About the Company
We do not have any company description for Candel Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Candel Therapeutics, Inc.
Candel Therapeutics Extends Lease Agreement in Needham
Candel Therapeutics ( ($CADL) ) has issued an announcement. On August 18, 2025, Candel Therapeutics Inc. extended its lease agreement for its ...
Candel Therapeutics Advances with Promising Cancer Therapies
Candel Therapeutics, Inc. ( ($CADL) ) has released its Q2 earnings. Here is a breakdown of the information Candel Therapeutics, Inc. presented to ...
Candel Therapeutics, Inc. Gains Inclusion in Multiple Russell Value ...
Candel Therapeutics, Inc., a biopharmaceutical company focused on cancer immunotherapies, announced its addition to several Russell indexes following the 2025 annual reconstitution, effective June ...
Candel Therapeutics, Inc. Announces Appointment of Maha ... - Nasdaq
Candel Therapeutics, Inc. Announces Appointment of Maha Radhakrishnan, M.D. to Board of Directors June 06, 2025 — 08:12 am EDT Written by None for Quiver Quantitative -> ...
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene ...
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of ...
NEEDHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal ...
What's Going On With Candel Therapeutics Stock?
Candel Therapeutics, Inc. (NASDAQ:CADL) shares are trading higher Thursday after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer. "We ...
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual ...
NEEDHAM, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal ...
Candel Therapeutics Inc call volume above normal and directionally ...
Bullish option flow detected in Candel Therapeutics (CADL) Inc with 2,179 calls trading, 1.2x expected, and implied vol increasing almost 2 points to 150.18%. Dec-24 7 calls and Dec-24 9 calls are ...
Candel Therapeutics Sets Stage For Success With Cancer-Fighting ...
Candel and collaborators at the Brigham and Women’s Hospital published in the high-impact journal Nature that CAN-3110 was well tolerated with no dose-limiting toxicity reported.
Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting ...
Candel Therapeutics, Inc. released positive interim results from the phase 2 study using CAN-2409 for treatment of patients with pancreatic ductal adenocarcinoma; Patients that took the drug with ...
Similar Companies
Loading the latest forecasts...